Literature DB >> 7986223

Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients.

C Bologna1, L Edno, J M Anaya, F Canovas, M Vanden Berghe, C Jorgensen, M Galtier, B Combe, F Bressolle, J Sany.   

Abstract

OBJECTIVE: To determine methotrexate (MTX) concentrations in the synovial membrane (SM) and cortical and trabecular bone of rheumatoid arthritis (RA) patients.
METHODS: Ten RA patients (9 women, 1 man; mean +/- SD age 49.2 +/- 10.6, mean disease duration 13.2 +/- 9.9 years) undergoing surgical procedures for rheumatoid articular lesions participated in this study. Mean +/- SD MTX treatment duration was 26.4 +/- 21.3 months. The day preceding surgery, 10 mg of MTX was administered intramuscularly. During surgery, a mean +/- SD of 19.7 +/- 2.6 hours after MTX administration, SM, bone fragments, and blood were collected simultaneously. MTX was assayed by fluorescence polarization immunoassay in plasma and tissues.
RESULTS: The mean +/- SD plasma concentration was 0.0252 +/- 0.01 nmoles/ml at the time of tissue sampling. The mean MTX concentration in SM was 0.285 +/- 0.159 nmoles/gm. The mean MTX concentrations in trabecular and cortical bone were 0.292 +/- 0.164 and 0.286 +/- 0.126 nmoles/gm, respectively.
CONCLUSION: After intramuscular administration, high MTX concentrations are found in SM and cortical and trabecular bone of RA patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986223     DOI: 10.1002/art.1780371210

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression.

Authors:  M F Neurath; K Hildner; C Becker; J F Schlaak; K Barbulescu; T Germann; E Schmitt; P Schirmacher; S Haralambous; M Pasparakis; K H Meyer Zum Büschenfelde; G Kollias; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism.

Authors:  Addolorata Corrado; Anna Neve; Arcangela Marucci; Annamaria Gaudio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2014-08-23       Impact factor: 3.984

3.  Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis.

Authors:  K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 4.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 5.  Osteoporosis.

Authors:  R Cimaz; M Biggioggero
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

6.  Incidence and risk factors for vertebral fracture in rheumatoid arthritis: an update meta-analysis.

Authors:  Yang Liu; Jun Jiang; Minmin Mo; Xiaohong Sun; Kailong Yu
Journal:  Clin Rheumatol       Date:  2022-01-10       Impact factor: 2.980

Review 7.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients.

Authors:  Wako Urano; Takefumi Furuya; Eisuke Inoue; Atsuo Taniguchi; Tomohiko Urano; Shigeru Kotake; Chieko Sekita; Satoshi Inoue; Masako Hara; Shigeki Momohara; Naoyuki Kamatani; Hisashi Yamanaka
Journal:  J Bone Miner Metab       Date:  2009-03-31       Impact factor: 2.626

9.  Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis.

Authors:  A Nakajima; M Hakoda; H Yamanaka; N Kamatani; S Kashiwazaki
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

10.  Short time administration of antirheumatic drugs - methotrexate as a strong inhibitor of osteoblast's proliferation in vitro.

Authors:  Tobias Annussek; Johannes Kleinheinz; Szuwart Thomas; Ulrich Joos; Kai Wermker
Journal:  Head Face Med       Date:  2012-09-29       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.